|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Fate Therapeutics (NASDAQ: FATE) through any online brokerage.
The latest price target for Fate Therapeutics (NASDAQ: FATE) was reported by Citigroup on November 9, 2021. The analyst firm set a price target for 87.00 expecting FATE to rise to within 12 months (a possible 65.65% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Fate Therapeutics (NASDAQ: FATE) is $52.52 last updated Fri Nov 26 2021 18:00:04 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Fate Therapeutics.
Fate Therapeutics’s $Q4 earnings are confirmed for after-market on February 23, 2022.
There is no upcoming split for Fate Therapeutics.
Fate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.